Navigation Links
Why do certain diseases go into remission during pregnancy?
Date:6/16/2010

ANN ARBOR, MI -- During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.

The expression of an enzyme known as pyruvate kinase is reduced in immune cells in pregnant women compared to non-pregnant women, according to Howard R. Petty, Ph.D., biophysicist at the University of Michigan Kellogg Eye Center and Roberto Romero, M.D., of the National Institutes for Health. The study, which appears online ahead of print in the August issue of the American Journal of Reproductive Immunology, also reports that expression of the enzyme is lower in pregnant women compared to those with pre-eclampsia, a condition with inflammatory components.

The study is significant because the newly discovered mechanism points to a pathway that could be targeted for treatment. "It may be possible to design drugs that mildly suppress pyruvate kinase activity as a means of replicating the immune status of normal pregnancy," says Petty. In addition to pre-eclampsia, he believes that rheumatoid arthritis, type 1 diabetes, and uveitis may eventually yield to similarly designed drugs.

In his search to explain the phenomenon, Petty knew to look for a metabolic pathway or mechanism with two characteristics. It had to "dial down" the intensity of the normal immune response, an action needed so that a pregnant woman does not reject the fetus, which has proteins from the father that are "foreign" to the mother. At the same time, such a mechanism must support cell growth needed by the developing fetus.

The activity of the enzyme pyruvate kinaseand and its product, pyruvatefills both roles: promoting cell growth while modifying the immune response. Because pyruvate kinase activity is depressed during pregnancy, cell metabolism supports an increased production of lipids, c
'/>"/>

Contact: Betsy Nisbet
bsnisbet@umich.edu
734-647-5586
University of Michigan Health System
Source:Eurekalert

Page: 1 2

Related biology news :

1. Medical researchers discovery may explain how certain cancers develop
2. Long-term use of certain contraception injections associated with increased fracture risk
3. Mango effective in preventing, stopping certain colon, breast cancer cells
4. Ongoing human evolution could explain recent rise in certain disorders
5. Consumption of certain fish during pregnancy associated with poorer cognitive performance
6. MSU discoveries upend traditional thinking about how plants make certain compounds
7. Shellfish face an uncertain future in a high CO2 world
8. New evidence explains poor infant immune response to certain vaccines, says MU researcher
9. Study unravels why certain fishes went extinct 65 million years ago
10. Dealing with taxonomic uncertainty for threatened and endangered species
11. UCSB scientists show how certain vegetables combat cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E - ... authentication solutions, today announced it will showcase its EyeLock ID ... by the Department of Energy,s Oak Ridge National Laboratory ... Show . EyeLock,s iris identity authentication technology is being used ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... causing the largest die-off of great whales ever recorded? ... and health experts from the Wildlife Conservation Society have ... by the International Whaling Commission on the Patagonian coast ... urgent mystery. At issue is the long-term conservation ...
... D.C., March 16, 2010 Primary care physicians agree they ... not have the right weight management resources. Obese or ... need to lose weight may lack information about effective weight ... from new research commissioned and released today by the Strategies ...
... National Foundation for Cancer Research announced today that renowned ... of Molecular and Experimental Medicine at The Scripps Research ... 5th Annual Szent-Gyrgyi Prize for Progress in Cancer Research. ... humble chicken virus in the early 1960s, has profoundly ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 2STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 35th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 25th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 3
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
(Date:2/26/2015)... -- Epic Sciences announced today that President and CEO ... Annual Cowen and Company Health Care Conference on Wednesday, March ... Floor. The conference will be held at the Boston ... is developing diagnostic tests of high clinical utility to ... occur during the course of cancer treatments. From a ...
(Date:2/26/2015)... SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2015 ... for the treatment of cancer, today announced that ... present a corporate overview at the upcoming Cowen and ... Boston . Dr. McCarthy,s presentation will ... 2. About CytomX Therapeutics CytomX Therapeutics ...
(Date:2/26/2015)... , February 26, 2015 ... into PEACH, the first pivotal trial of PT20 ... chronic kidney disease (DD-CKD), has completed as the ... PT20, invented by leading UK-based scientists from ... Phosphate Therapeutics, is a novel phosphate binder that ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: OGXI ) announced ... Fast Track designation from the U.S. Food & ... prostate cancer. OGX-011 is currently completing five Phase ... and is designed to,inhibit the production of a ...
... 21 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... on August 25, 2008 at 11:00 am MDT ... the presentation there will be a live,question and ... at the following link:, http://services.choruscall.com/links/resverlogix080825.html , ...
... BPUR ) today announced its financial results for the ... the company reported a net,loss of $4.6 million, or ... $6.4 million, or $0.41 per common share, for the ... July 31, 2008 and 2007 were,37,340,051 and 15,592,025, respectively., ...
Cached Biology Technology:FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Resverlogix Notice of Conference Call & Webcast 2Biopure Announces 2008 Third Quarter Financial Results 2Biopure Announces 2008 Third Quarter Financial Results 3Biopure Announces 2008 Third Quarter Financial Results 4Biopure Announces 2008 Third Quarter Financial Results 5Biopure Announces 2008 Third Quarter Financial Results 6Biopure Announces 2008 Third Quarter Financial Results 7
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: